StreetInsider.com News Articles

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Announces 2025 Annual Results

Mon, 30 Mar 2026 08:56:00 -0400

HANGZHOU, China, March 30, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2025 (the "Reporting Period").

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 annual results announcement and other relevant announcements published on the

Tigermed Selected as "2025 Forbes China Go-International Flagship Brands" Top 30

Thu, 06 Nov 2025 05:08:00 -0400

HANGZHOU, China, Nov. 6, 2025 /PRNewswire/ -- Tigermed has been selected as one of the Top 30 companies on the "2025 Forbes China Go-International Flagship Brands" list, Forbes China announced Tuesday.